10.11  -1.57 (-13.44%)		04-26 16:00
Open: 11.06 High: 11.07 Volume: 100,696		Pre. Close: 11.68 Low: 9.63 Market Cap: 331(M)

Short term
Mid term
Targets	6-month :	12.83	1-year :	14.13
Resists	First :	10.98	Second :	12.1
Pivot price	10.86
Supports	First :	9.18	Second :	7.64
MAs	MA(5) :	11.04	MA(20) :	10.94
	MA(100) :	0	MA(250) :	0
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	74.7	D(3) :	79.5
RSI	RSI(14): 44.6
52-week	High :	19.6	Low :	6.53

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ FBLG ] has closed above bottom band by 17.2%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	11.08 - 11.13	11.13 - 11.17
Low:	9.51 - 9.58	9.58 - 9.62
Close:	10.01 - 10.12	10.12 - 10.18

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Sun, 04 Feb 2024
StockWatch: Alto, Fractyl, FibroBiologics Join Parade of Public Biotechs - Genetic Engineering & Biotechnology News

Thu, 01 Feb 2024
FibroBiologics Stock (NASDAQ:FBLG), Quotes and News Summary - Benzinga

Wed, 31 Jan 2024
FibroBiologics goes public through direct listing on Nasdaq (NASDAQ:FBLG) - Seeking Alpha

Wed, 31 Jan 2024
FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG - PR Newswire

Mon, 29 Jan 2024
Houston regenerative medicine company to IPO, move toward more human trials - InnovationMap

Wed, 24 Jan 2024
FibroBiologics to go public via direct listing on Jan. 31 (Pending:FBLG) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	33 (M)
Shares Float	23 (M)
Held by Insiders	30.3 (%)
Held by Institutions	0 (%)
Shares Short	1 (K)
Shares Short P.Month	7 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-66.8 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.28
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	4 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-51.69

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.